Two-Part Ebola Vaccine Regimen may Offer Protection for a Year

by Bidita Debnath on  March 15, 2017 at 11:51 PM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

A two-part Ebola vaccine regimen has been found to offer protection against the deadly disease for about a year in an early human trial.
Two-Part Ebola Vaccine Regimen may Offer Protection for a Year
Two-Part Ebola Vaccine Regimen may Offer Protection for a Year

The vaccine regimen induced an immune response that persisted for approximately one year in healthy adult volunteers, according to results from the phase-1 clinical trial published in the Journal of the American Medical Association.

The experimental vaccines included Ad26.ZEBOV, developed by Johnson & Johnson, and MVA-BN-Filo, developed by Denmark-based Bavarian Nordic.

Both of the vaccines in the regimen use harmless viral vectors, or carriers, to deliver proteins of the Ebola virus, which prompt an immune response.

The trial, conducted by Matthew D. Snape of the University of Oxford and colleagues, enrolled healthy participants aged 18-50 years in Britain.

Participants were selected randomly to receive either the two-vaccine regimen or placebo (saltwater injections).

Previously reported initial results showed the two-vaccine regimen is safe, well-tolerated and induced immune responses in participants eight months after immunisation.

Of the 75 participants who received the vaccine regimen, 64 remained in the study for a follow-up visit on day 360.

No serious vaccine-associated adverse events were observed, and all 64 participants maintained antibodies to Ebola virus at day 360.

The researchers noted that additional research is necessary to assess the durability of immunity beyond one year and the immune response to booster doses of vaccine.

Source: IANS

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

Recommended Reading

More News on:

Amyotrophic Lateral Sclerosis (ALS) Congo Fever Vaccination for Children Ebola Virus Disease Top 10 Vaccine Myths Debunked 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive